Why Does Sex Hurt After Menopause? Causes, Treatments, and When to Ask for Help

What Is Actually Happening to Vaginal Tissue After Menopause

Estrogen loss changes the physical structure of the vagina and vulva within months of the final menstrual period. Before menopause, estrogen keeps vaginal epithelium thick, well-glycogenated, and home to lactobacillus species that maintain a low pH around 4.5. After menopause, circulating estradiol falls from roughly 100 to 200 pg/mL during the reproductive years to below 20 pg/mL, and often below 10 pg/mL in the late postmenopause [1]. That hormonal shift causes the stratified squamous epithelium to thin from roughly 20 cell layers to 4 or 5, collagen content drops, vaginal rugae flatten, and the introitus narrows [2].

The result is a tissue that tears easily, bleeds on contact, and cannot generate adequate lubrication during arousal. The pH rises above 6, which also increases susceptibility to bacterial vaginosis and recurrent UTIs. Penetration becomes painful because there is less moisture, less elasticity, and less space. Many women describe the sensation as tearing, burning, or the feeling of "sandpaper." Some notice post-coital spotting.

The 2022 NAMS Position Statement on Hormone Therapy uses the updated diagnostic term Genitourinary Syndrome of Menopause (GSM), which covers vaginal, vulvar, and lower urinary tract symptoms together because they share the same estrogen-dependent pathophysiology [3]. GSM affects an estimated 27% to 84% of postmenopausal women depending on assessment method, yet fewer than 25% of affected women receive any treatment, partly because clinicians do not routinely ask and patients assume it is unavoidable [4].

Unlike vasomotor symptoms (hot flashes, night sweats) that often improve over time without treatment, GSM does not self-resolve. Tissue atrophy typically worsens with each additional year of estrogen deficiency.

Is Low Libido in Women Hormonal?

Low libido after menopause has hormonal roots, but the picture involves more than one hormone. Both estrogen and testosterone drop significantly at menopause, and each contributes through a different mechanism.

Estrogen loss drives GSM and pain. When sex hurts, desire predictably falls. That is a conditioned behavioral response, not a character flaw. Restoring tissue comfort through local or systemic estrogen often partially restores desire on its own [5].

Testosterone plays a separate role. Women produce testosterone in the ovaries and adrenal glands throughout their reproductive life. Total testosterone in women ranges from approximately 15 to 70 ng/dL in the mid-reproductive years, then declines steadily from the late 20s onward. Surgical menopause (bilateral oophorectomy) causes an abrupt 40% to 50% drop in testosterone within days of surgery [6]. Natural menopause causes a more gradual decline, though ovarian testosterone production continues for years after the final period because luteinizing hormone (LH) still stimulates theca cells.

Progesterone levels also fall to near zero after menopause. Some researchers propose that progesterone has direct central nervous system effects on sexual desire through GABA-A receptors, though the clinical evidence for progesterone-specific libido effects remains less clear than for estrogen and testosterone.

Stress, disrupted sleep (both common in perimenopause), relationship factors, depression, and medications, particularly SSRIs and SNRIs, all add to the hormonal picture. A woman with perfectly replaced hormones but undertreated depression may still have low desire. Treatment that ignores the non-hormonal contributors rarely produces complete recovery.

What Is HSDD and How Is It Diagnosed?

Hypoactive Sexual Desire Disorder (HSDD) is the most common female sexual dysfunction, affecting approximately 10% of all adult women and a higher proportion of postmenopausal women [7]. The DSM-5 merged it with female sexual arousal disorder into Female Sexual Interest/Arousal Disorder (FSIAD), but HSDD remains the term used in most clinical trials and the two FDA-approved drug labels.

The diagnostic criteria require persistently low or absent sexual desire that causes personal distress. That distress clause matters. A woman who has low desire and is entirely at peace with it does not meet the clinical threshold. The condition is diagnosed by exclusion after ruling out relationship problems as the sole driver, underlying mood disorders, and medication side effects.

No single lab value diagnoses HSDD. Clinicians use validated tools such as the Female Sexual Function Index (FSFI), the Decreased Sexual Desire Screener (DSDS), or the Brief Profile of Female Sexual Function (B-PFSF). Total and free testosterone levels, TSH, prolactin, and estradiol are measured to identify correctable contributors, but HSDD can persist even when hormone levels fall within reference ranges.

The FDA has approved two drugs specifically for HSDD. Flibanserin (Addyi, 100 mg nightly) targets central serotonin and dopamine pathways and received approval in 2015 for premenopausal women with acquired, generalized HSDD [8]. Bremelanotide (Vyleesi, 1.75 mg subcutaneous as-needed) is a melanocortin receptor agonist approved in 2019 for the same indication, with some post-approval use extending to postmenopausal women in clinical practice [9]. Neither drug is a hormone, and neither treats the tissue changes of GSM.

Does HRT Increase Libido?

Systemic hormone therapy (HRT) reliably improves libido when pain or discomfort was the main barrier to sex, but the effect on desire itself is more variable. The mechanism differs by component.

Systemic estradiol (oral, transdermal patch, gel, or spray) raises circulating estrogen, reverses GSM tissue changes throughout the genital tract, and reduces hot flashes and night sweats that fragment sleep. When sleep improves and sex no longer hurts, desire often follows. The REPLENISH trial (N=1,835), a phase 3 study of a combined estradiol/progesterone capsule (Bijuva), documented significant improvements in vaginal dyspareunia and dryness scores at 12 weeks compared to placebo [10].

Systemic HRT does not significantly raise free testosterone because estrogen increases sex hormone-binding globulin (SHBG), which binds testosterone and reduces the bioavailable fraction. Some women on oral estrogen actually notice a decline in desire because SHBG rises enough to lower free testosterone below its already-reduced postmenopausal level. Transdermal estradiol causes a smaller SHBG rise than oral formulations, making it a better choice for women in whom libido is a primary concern [11].

Progestogens differ in their libido impact. Micronized progesterone (Prometrium, Utrogestan) appears more neutral or mildly positive on sexual function compared to synthetic progestins such as medroxyprogesterone acetate (MPA), which in some studies is associated with reduced desire and mood [12]. The KEEPS trial found that transdermal estradiol with oral progesterone improved sexual function more than oral conjugated equine estrogen with MPA over 48 months.

The HealthRX clinical team uses the following decision framework when a postmenopausal patient reports painful sex and low desire:

Step 1. Confirm and treat GSM first. Local vaginal estradiol 10 mcg twice weekly (Vagifem, Yuvafem) or 4 mcg (Imvexxy) typically resolves dryness and dyspareunia within 8 to 12 weeks with minimal systemic absorption. For women who prefer to avoid any estrogen, ospemifene 60 mg daily or intravaginal DHEA (prasterone, Intrarosa) 6.5 mg nightly are FDA-approved non- or low-systemic-estrogen options.

Step 2. If the patient also has vasomotor symptoms or bone density concerns, evaluate for systemic HRT. Choose transdermal estradiol over oral to limit SHBG elevation. Add micronized progesterone for uterine protection.

Step 3. Reassess desire at 12 weeks. If desire remains low after GSM and sleep are addressed, evaluate free testosterone and screen for depression, medication side effects, and relationship distress.

Step 4. Consider off-label testosterone if free testosterone is low, other causes have been addressed, and the patient remains distressed by low desire.

Step 5. Refer to a certified sex therapist or pelvic floor physical therapist for cases involving significant psychological overlay, vaginismus, or pelvic floor hypertonicity.

Can Testosterone Help Women's Libido?

Off-label testosterone therapy has the strongest evidence base of any intervention specifically targeting female sexual desire. A 2019 systematic review and meta-analysis in The Lancet Diabetes and Endocrinology (Davis et al., 36 RCTs, N=8,480) found that testosterone therapy significantly improved sexual function scores, including desire, arousal, and frequency of satisfying sexual events, across both surgical and natural menopause [13]. The effect size was moderate to large compared with placebo.

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women, co-published by multiple endocrine and gynecologic societies, concludes: "There is sufficient evidence to support testosterone therapy for postmenopausal women with HSDD" [14]. That statement, published in 2019, covers both natural and surgically menopausal women and specifies that doses should be physiologic, targeting the upper half of the normal female range rather than supraphysiologic male doses.

No testosterone product carries an FDA indication for women in the United States. Clinicians prescribe compounded testosterone creams (typically 1 to 2 mg/day applied to the inner thigh or vulva) or low-dose testosterone pellets, though pellets carry higher risk of supraphysiologic levels. The Endo International guidelines recommend monitoring total and free testosterone at baseline and at 3 to 6 weeks after initiation, then every 6 months, targeting total testosterone below 150 ng/dL to avoid androgenic side effects such as acne or clitoral sensitivity [15].

One practical point: testosterone and local estrogen often work better together than alone for postmenopausal sexual dysfunction. Testosterone raises desire; local estrogen makes acting on that desire comfortable.

Local Vaginal Estrogen: What to Expect and How to Use It

Local vaginal estrogen is the most evidence-supported prescription treatment for GSM and remains the most under-prescribed. The options include:

Vaginal cream. Conjugated estrogen cream (Premarin vaginal) or estradiol cream (Estrace vaginal). Dosed at 0.5 g intravaginally 3 times per week for maintenance after an initial loading phase of nightly use for 2 weeks. The cream can also be applied externally to the vulvar vestibule for women with burning or splitting at the introitus.

Vaginal tablet or insert. Estradiol 10 mcg (Vagifem, Yuvafem) or 4 mcg (Imvexxy). Inserted with an applicator twice weekly. The 4 mcg dose delivers the lowest systemic absorption of any estradiol product and is often chosen for breast cancer survivors (though formal FDA approval in that population is absent).

Vaginal ring. Estring releases 7.5 mcg estradiol per 24 hours continuously for 90 days. Patients insert and remove it themselves; it requires changing only four times per year, which suits women with adherence challenges.

A 2023 Cochrane review of 46 trials (N=4,984) comparing vaginal estrogen preparations to placebo or each other found all formulations significantly better than placebo for reducing vaginal dryness, dyspareunia, and pH at 12 weeks, with no statistically significant differences in efficacy between formulations [16]. Choice is therefore driven by patient preference, convenience, and cost.

Serum estradiol levels with local low-dose products typically remain below 20 pg/mL, within the postmenopausal reference range. The NAMS 2022 position statement concludes that for women with an intact uterus using only low-dose local vaginal estrogen, adding a progestogen for endometrial protection is not required [3]. That is an important reassurance for women who want to avoid systemic hormones.

Non-Hormonal Options for GSM and Low Libido

Not every woman can or wants to use hormones. Several non-hormonal treatments have meaningful evidence.

Ospemifene (Osphena) 60 mg oral daily is a selective estrogen receptor modulator (SERM) with agonist effects on vaginal tissue and the bone, and antagonist effects in breast tissue. A phase 3 trial (N=826 to 12 weeks) showed ospemifene reduced the most bothersome GSM symptom score by 2.5 points versus 1.5 points for placebo (P<0.001) and improved vaginal cell maturation index significantly [17]. It requires a progestogen if the uterus is present because of its mild endometrial agonist activity.

Intravaginal DHEA (prasterone, Intrarosa) 6.5 mg nightly converts locally to both estradiol and testosterone inside vaginal cells. A phase 3 trial (N=412 to 12 weeks) showed significant improvement in the most bothersome symptom and in sexual function scores versus placebo [18]. Systemic hormone levels remain within postmenopausal ranges.

Vaginal moisturizers used three times weekly (Replens, Good Clean Love) have been shown in small RCTs to reduce vaginal dryness scores comparably to local estrogen over 12 weeks in some studies, though long-term tissue remodeling data favor estrogen [19].

Pelvic floor physical therapy is underutilized. Women with GSM often develop secondary vaginismus, a reflex tightening of the levator ani and bulbocavernosus in anticipation of pain. No topical treatment resolves that conditioned muscle response; a trained pelvic floor PT can. A 2021 RCT published in the American Journal of Obstetrics and Gynecology found that pelvic floor PT combined with local estrogen reduced dyspareunia scores significantly more than local estrogen alone at 16 weeks [20].

Medications and Conditions That Make Things Worse

Several common drug classes reduce lubrication, desire, or both, and are often overlooked during a menopause workup.

SSRIs and SNRIs cause sexual dysfunction in 30% to 70% of users, including reduced lubrication, anorgasmia, and blunted desire [21]. Bupropion is the notable exception; it has a lower rate of sexual side effects and may even improve desire in some patients. If an SSRI is medically necessary, adding buspirone 15 mg twice daily or switching to bupropion augmentation may partially offset sexual side effects.

Antihistamines, some antihypertensives (particularly beta-blockers and thiazides), and long-term oral contraceptive pills (which raise SHBG and lower free testosterone) all reduce sexual function. The OCP-SHBG effect may persist for months after pill discontinuation in some women.

Hypothyroidism reduces libido directly. TSH should be checked in any woman presenting with new-onset low desire.

How Long Does It Take for Treatments to Work?

Vaginal tissue takes time to remodel. Women often expect immediate relief and stop treatment prematurely.

Local vaginal estrogen: initial moisture improvement in 2 to 4 weeks, meaningful reduction in dyspareunia by 8 to 12 weeks, and maximum tissue effect at 6 months of consistent use.

Ospemifene: pain scores improve significantly by week 4 in clinical trials, with full benefit at 12 weeks.

Systemic HRT: vasomotor and sleep improvements begin within 2 to 4 weeks; full libido benefit takes 3 to 6 months, particularly if testosterone is also being titrated.

Off-label testosterone: most women report improved desire within 4 to 6 weeks. The Lancet meta-analysis noted that peak sexual function improvements occurred at 6 weeks for validated desire scores in the majority of included trials [13].

Starting treatment and reassessing at 12 weeks is the standard clinical approach. If one agent fails to produce adequate relief by 12 weeks, combining strategies (for example, local estrogen plus testosterone for the patient with both GSM and HSDD) is reasonable and supported by guidelines.